From mechanism to therapies in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 29, Issue 2, 2017, Pages 178-186

  Paley, Michael A ^a   Strand, Vibeke ^b   Kim, Alfred H J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Lupus; Lupus pathogenesis; Novel therapeutics; Systemic lupus erythematosus; Targeted therapy

Indexed keywords

B CELL ACTIVATING FACTOR; BRUTON TYROSINE KINASE; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; JANUS KINASE; LIGAND; 5-AMINO-1-(1-CYANOPIPERIDIN-3-YL)-3-(4-(2,4-DIFLUOROPHENOXY)PHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ALPHA INTERFERON; BELIMUMAB; CLAZAKIZUMAB; CYTOKINE; HYBRID PROTEIN; IBRUTINIB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; ISOQUINOLINE DERIVATIVE; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB; RN486; RONTALIZUMAB; SIFALIMUMAB; SIRUKUMAB; STAT PROTEIN; STATTIC; SULFOXIDE; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

CLINICAL TRIAL (TOPIC); HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS; METABOLISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; DRUG APPROVAL; DRUG DEVELOPMENT; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; CYCLIC S-OXIDES; CYTOKINES; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERLEUKIN-17; INTERLEUKIN-6; ISOQUINOLINES; JANUS KINASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PIPERIDINES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECOMBINANT FUSION PROTEINS; RITUXIMAB; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85010843566     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000369     Document Type: Review

References (117)

1. Harley IT, Kaufman KM, Langefeld C.D., et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009; 10:285-290.
2. Ballestar E. Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol 2011; 7:263-271.
3. Rahman A, Isenberg DA Systemic lupus erythematosus. N Engl J Med 2008; 358:929-939.
4. Moore PA, Belvedere O, Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285:260-263.
5. Gross JA, Johnston J, Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995-999.
6. Schiemann B, Gommerman JL, Vora K, et al An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293:2111-2114.
7. Gross JA, Dillon SR, Mudri S, et al TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289-302.
8. Hsu BL, Harless SM, Lindsley R.C., et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168:5993-5996.
9. Do RK, Hatada E, Lee H., et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192:953-964.
10. Craxton A, Draves KE, Gruppi A, Clark EA BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005; 202:1363-1374.
11. Cheema GS, Roschke V, Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313-1319.
12. Stohl W, Metyas S, Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48:3475-3486.
13. Stohl W, Merrill JT, Looney R.J., et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist 'peptibody' blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther 2015; 17:215.
14. Edwards JC, Szczepanski L, Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
15. van Assen S., Holvast A, Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81.
16. Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64-74.
17. Shakoory B, Clatham W. Efficacy and safety data of belimumab in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2011; 3:159-164.
18. Jacobi AM, Huang W, Wang T., et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62:201-210.
19. van Vollenhoven R.F., Petri MA, Cervera R, et al Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343-1349.
20. Roth DA, Thompson A, Tang Y., et al. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 2016; 25:346-354.
21. Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 2014; 13:173-174.
22. Isenberg DA, Petri M, Kalunian K., et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75:323-331.
23. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75:332-340.
24. Benson MJ, Dillon SR, Castigli E, et al Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180:3655-3659.
25. Shah HB, Joshi SK, Rampuria P, et al BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol 2013; 191:1154-1163.
26. Jacob CO, Guo S, Jacob N., et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012; 64:1610-1619.
27. Huard B, Tran NL, Benkhoucha M, et al Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 2012; 7:e31837.
28. Ginzler EM, Wax S, Rajeswaran A., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012; 14:R33.
29. Isenberg D, Gordon C, Licu D., et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015; 74:2006-2015.
30. Gordon C, Wofsy D, Wax S., et al. Posthoc analysis of the Phase II/III APRILSLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol 2016; 69:122-130.
31. Fraser P, Chin W, Kao A. Atacicept: integrated safety profile from phase II randomized placebo-controlled studies in autoimmune diseases. Poster presented at: American College of Rheumatology Annual Meeting; November, 2016; Washington DC.
32. Merrill JT, Wallace D, Wax S., et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, phase IIb study. Poster presented at: American College of Rheumatology Annual Meeting; November, 2016; Washington DC.
33. Shlomchik MJ, Madaio MP, Ni D, et al The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180:1295-1306.
34. Chan OT, Hannum LG, Haberman A.M., et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639-1648.
35. Cohen SB, Emery P, Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
36. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol 2016; 12:367-372.
37. Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis 2015; 18:154-163.
38. Mahieu MA, Strand V, Simon L.S., et al. A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016; 25:1122-1140.
39. Carter LM, Isenberg DA, Ehrenstein MR Elevated serum BAFF levels are associated with rising antidouble-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013; 65:2672-2679.
40. Simonetta F, Allali D, Roux-Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine 2016; http://dx.doi.org/10.1016/j.jbspin.2016.01.008.
41. Kerkman PF, Rombouts Y, van der Voort EI, et al. Circulating plasmablasts/ plasmacellsas a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1259-1263.
42. Liu Z, Zou Y, Davidson A. Plasma cells in systemic lupus erythematosus: the long and short of it all. Eur J Immunol 2011; 41:588-591.
43. Grammer AC, Lipsky PE B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5 (suppl 4):S22-27.
44. St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum 2010; 62:1-5.
45. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63:3038-3047.
46. Lazarus MN, Turner-Stokes T, Chavele K.M., et al. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to antidsDNA antibody levels. Rheumatology (Oxford) 2012; 51:1208-1215.
47. Neubert K, Meister S, Moser K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-755.
48. Frohlich K, Holle JU, Aries P.M., et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011; 70:1344-1345.
49. Alexander T, Sarfert R, Klotsche J., et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74:1474-1478.
50. Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol 2016; 12:232-240.
51. Crofford LJ, Nyhoff LE, Sheehan J.H., Kendall PL. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol 2016; 12:763-773.
52. Di Paolo J.A., Huang T, Balazs M., et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7:41-50.
53. Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for Bcell activation and negative selection of autoreactive B cells in mice. Blood 2012; 119:3744-3756.
54. Hutcheson J, Vanarsa K, Bashmakov A., et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther 2012; 14:R243.
55. Mina-Osorio P., LaStant J, Keirstead N., et al. Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum 2013; 65:2380-2391.
56. Rankin AL, Seth N, Keegan S., et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol 2013; 191:4540-4550.
57. Chang BY, Huang MM, Francesco M, et al The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13:R115.
58. Hooks JJ, Moutsopoulos HM, Geis S.A., et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301:5-8.
59. Mathian A, Weinberg A, Gallegos M., et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174:2499-2506.
60. Santiago-Raber M.L., Baccala R, Haraldsson K.M., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197:777-788.
61. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20:15-25.
62. Agrawal H, Jacob N, Carreras E., et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183:6021-6029.
63. Liu Z, Davidson A. IFNalpha inducible models of murine SLE. Front Immunol 2013; 4:306.
64. Sisirak V, Ganguly D, Lewis K.L., et al. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med 2014; 211:1969-1976.
65. Baechler EC, Batliwalla FM, Karypis G, et al Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100:2610-2615.
66. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-723.
67. Feng X, Wu H, Grossman J.M., et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951-2962.
68. Yao Y, Richman L, Higgs B.W., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an antiinterferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785-1796.
69. Yao Y, Higgs BW, Richman L, et al Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12 (Suppl 1):S6.
70. Mathian A, Hie M, Cohen-Aubart F, Amoura Z. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 2015; 75:835-846.
71. Kalunian KC, Merrill JT, Maciuca R, et al A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016; 75:196-202.
72. Khamashta M, Merrill JT, Werth V.P., et al. Sifalimumab, an antiinterferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75:1909-1916.
73. Narain S, Furie R. Update on clinical trials in systemic lupus erythematosus. Curr Opin Rheumatol 2016; 28:477-487.
74. Muller U, Steinhoff U, Reis L.F., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-1921.
75. Lauwerys BR, Hachulla E, Spertini F., et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013; 65:447-456.
76. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13:339-343.
77. Lu R, Munroe ME, Guthridge J.M., et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 2016; 74:182-193.
78. Linker-Israeli M., Deans RJ, Wallace D.J., et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147:117-123.
79. Umare V, Nadkarni A, Nadkar M., et al. Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosus patients? J Postgrad Med 2016; Available from: http://www.jpgmonline.com/preprintarticle.asp?id=188550.
80. Ryffel B, Car BD, Gunn H, et al Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994; 144:927-937.
81. Yang G, Liu H, Jiang M., et al. Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3-IL-6 on BXSB mice. Chin Med J (Engl) 1998; 111:38-42.
82. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/ NZW F1 mice. J Clin Invest 1994; 94:585-591.
83. Mihara M, Takagi N, Takeda Y., Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998; 112:397-402.
84. Liang B, Gardner DB, Griswold D.E., et al. Antiinterleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119:296-305.
85. Richards HB, Satoh M, Shaw M., et al. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998; 188:985-990.
86. Illei GG, Shirota Y, Yarboro C.H., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542-552.
87. Szepietowski JC, Nilganuwong S, Wozniacka A., et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013; 65:2661-2671.
88. Rovin BH, van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 2016; 68:2174-2183.
89. Wallace DJ, Strand V, Merrill J.T., et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis 2016; https://dx.doi.org/10.1136/annrheumdis-2016-209668.
90. Weinblatt ME, Mease P, Mysler E., et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 2015; 67:2591-2600.
91. Mease PJ, Gottlieb AB, Berman A, et al The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol 2016; 68:2163-2173.
92. Li D, Guo B, Wu H., et al. Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity 2015; 48:353-361.
93. Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol 2014; 154:1-12.
94. Hsu HC, Yang P, Wang J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9:166-175.
95. Pisitkun P, Ha HL, Wang H, et al Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012; 37:1104-1115.
96. Lourenco EV, La Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med 2009; 9:242-254.
97. Li J, Zhao S, Yi M., et al. Activation of JAK-STAT1 signal transduction pathway in lesional skin and monocytes from patients with systemic lupus erythematosus. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011; 36:109-115.
98. Dong J, Wang QX, Zhou C.Y., et al. Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 2007; 16:101-109.
99. Furumoto Y, Smith CK, Blanco L, et al Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol 2017; 69:148-160.
100. Ripoll E, de Ramon L, Draibe Bordignon J, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther 2016; 18:134.
101. Wang S, Yang N, Zhang L., et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 2010; 19:1171-1180.
102. Ding C, Chen X, Dascani P., et al. STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus. J Immunol 2016; 196:4477-4486.
103. Edwards LJ, Mizui M, Kyttaris V. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol 2015; 158:221-230.
104. Pearce EL, Poffenberger MC, Chang C.H., Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013; 342:1242454.
105. Gerriets VA, Kishton RJ, Johnson M.O., et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol 2016; 17:1459-1466.
106. Huang SC, Everts B, Ivanova Y., et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol 2014; 15:846-855.
107. Peng M, Yin N, Chhangawala S, et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 2016; 354:481-484.
108. Chang CH, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013; 153:1239-1251.
109. + T cells from both a murine model of SLE and SLE patients and how treatment with metformin and 2-deoxy-d-glucose normalised T-cell metabolism and improved disease.
110. Oh JR, Song HC, Kang S.R., et al. The clinical usefulness of (18)F-FDG PET/ CT in patients with systemic autoimmune disease. Nucl Med Mol Imaging 2011; 45:177-184.
111. + T cell activation in a mouse model of systemic lupus erythematosus. J Immunol 2016; 196:80-90.
112. Kato H, Perl A. Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4 - CD8 - double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol 2014; 192:4134-4144.
113. Agmon-Levin N., Mosca M, Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012; 11:593-595.
114. Banchereau R, Hong S, Cantarel B., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016; 165:551-565.
115. Putterman C, Wu A, Reiner-Benaim A, et al. SLE-key(R) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: developing the ImmunArray iCHIP(R). J Immunol Methods 2016; 429:1-6.
116. Budde P, Zucht HD, Vordenbaumen S, et al Multiparametric detection of autoantibodies in systemic lupus erythematosus. Lupus 2016; 25:812-822.
117. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793-795.